Seres Therapeutics, Inc. (MCRB)
MCRBNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$1.55
-0.1500 (-8.82%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.55 -0.64%
- Market cap
- $15.90m
- P/E
- –
- EPS, last 4 quarters
- $-6.53
- Dividend yield
- –
- Day range
- $1.55 to $1.74
- 52-week range
- $1.68 to $29.98
- Average volume
- 73.2k
- Previous close
- $1.70
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $17.00, +996.8% from here
Earnings
next estimate $-1.56Next report
Dec 2025
+20.9%
Mar 2026
–
Jun 2026
+27.5%
Sep 2026
+20.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $438.0k | $358.0k | $736.0k | $593.0k |
| Gross profit | $438.0k | $358.0k | $736.0k | $593.0k |
| Operating income | -$19.38m | -$20.91m | -$21.27m | -$16.15m |
| Net income | -$15.34m | -$19.91m | $4.58m | -$16.29m |
Last four quarters: revenue $2.13m, margin -2209.6%, free cash flow –
News
8 latest- Seres Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Outlines SER-155 Development PlansFintel · 6 days ago
- Seres Therapeutics (MCRB) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- Seres Therapeutics Swings To Q2 Profit; SER-155 Data Support Further Development In IrEC RTTNews · Aug 19, 2026
- Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity StudyMarketBeat · Jul 10, 2026
- 3 Beaten-Down Biotech Stocks to Buy for a 2026 TurnaroundZacks · Dec 29, 2025
- Seres Therapeutics (MCRB) Price Target Increased by 31.25% to 21.42Fintel · Dec 5, 2025
- Seres (MCRB) Q3 2025 Earnings Call TranscriptThe Motley Fool · Nov 5, 2025
- Seres Gets Constructive Feedback From FDA On Phase 2 Study Protocol For SER-155; To Cut Workforce RTTNews · Sep 23, 2025
The company
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics products in oncology that address causes of mortality and discontinuation of life-saving cancer treatment, and in inflammatory and immune (I&I) diseases, by modulating host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal (GI) tract. The Company previously led the development and FDA approval of VOWST, the first orally administered microbiome therapeutic, which was subsequently divested to Nestle Health Science.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- serestherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.